This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
For patients with chronic hepatitis B (CHB), achievement of subcirrhotic range of liver stiffness (sc-LS) with antiviral therapy (AVT) is associated with reduced risk of hepatocellular carcinoma (HCC), according to a study published in the Journal of Gastroenterology and Hepatology.
During the study period, the researchers found that after 2 years of AVT, 67.0% of patients achieved sc-LS and 13.4% of patients developed HCC.
“The achievement of sc-LS after AVT can reduce the risk of HCC development in patients with CHB, even when advanced fibrosis or cirrhosis is apparent on starting AVT,” the authors write.